CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Patrys Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Patrys Ltd
Level 4, 96-100 Albert Road
Phone: +61 396703273p:+61 396703273 SOUTH MELBOURNE, VIC  3205  Australia Ticker: PABPAB
Business Summary
Patrys Limited is an Australia-based company, which provides a proprietary deoxymab antibody technology platform to develop new therapies for the treatment of cancer and other diseases. The Company’s deoxymab platform is based on the deoxymab 3E10 antibody that is identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). It has developed two humanized forms of deoxymab 3E10, called PAT-DX1 and PAT-DX3, which have improved activity over the original 3E10 antibody. PAT-DX1 is a dimer of a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10. PAT-DX3 is a humanized, full-sized antibody that has been further optimized to improve its therapeutic potential. PAT-DX3 is likely to have clinical utility for treating primary and secondary brain cancers due to its ability to cross the blood brain barrier.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20256/30/2025Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Peter J.Christie 6/17/2025 6/17/2025
Vice President - Research and Development ValentinaDubljevic 1/1/2022 1/1/2021
Vice President - Corporate Development RebeccaTunstall 1/1/2022 1/1/2022
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Nucleus Therapeutics Pty Ltd
PAB
PABDA
Patrys Limited

General Information
Number of Employees: 15 (As of 6/30/2014)
Outstanding Shares: 305,599,053 (As of 10/13/2025)
Shareholders: 3,310
Stock Exchange: ASX
Fax Number: +61 396703247


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, December 6, 2025